World Library  
Flag as Inappropriate
Email this Article

Sb-277,011-a

Article Id: WHEBN0014095223
Reproduction Date:

Title: Sb-277,011-a  
Author: World Heritage Encyclopedia
Language: English
Subject: List of dopaminergic drugs, Dinoxyline, Nafadotride, SKF-89,145, AS-8112
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Sb-277,011-a

SB-277,011-A
Systematic (IUPAC) name
N-{trans-4-[2-(6-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]cyclohexyl}quinoline-4-carboxamide
Clinical data
Legal status
?
Identifiers
CAS number  YesY
ATC code ?
PubChem
IUPHAR ligand
ChEMBL  N
Chemical data
Formula C28H30N4O 
Mol. mass 438.563 g/mol
 N   

SB-277,011A is a drug which acts as a potent and selective dopamine D3 receptor antagonist,[1] which is around 80-100x selective for D3 over D2,[2] and lacks any partial agonist activity.[3]

SB-277,011A is used in the study of addiction to stimulant drugs such as nicotine[4] and cocaine.[5][6] Where cocaine reduces the threshold for brain electrical self-stimulation in rats, an indication of cocaine's rewarding effects, SB-277,011A completely reverses this effect. It may thus be useful in the treatment of addiction to nicotine and cocaine,[7][8][9] and is also being investigated for potential uses in the treatment of other drug addictions, such as addiction to heroin[10] and alcohol.[11][12][13]

Another potential application for SB-277,011A is in the treatment of schizophrenia,[14] and it may be particularly useful in treating comorbid patients who are both schizophrenic and addicted to drugs.[15] However it may worsen side effects such as tardive dyskinesia in patients who are already prescribed antipsychotic drugs.[16]

References

  1. ^ Stemp, G; Ashmeade, T; Branch, CL; Hadley, MS; Hunter, AJ; Johnson, CN; Nash, DJ; Thewlis, KM et al. (2000). "Design and synthesis of trans-N-4-2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethylcyclohexyl-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat". Journal of Medical Chemistry 43 (9): 1878–85.  
  2. ^ Southam, E; Lloyd, A; Jennings, CA; Cluderay, JE; Cilia, J; Gartlon, JE; Jones, DN (2007). "Effect of the selective dopamine D3 receptor antagonist SB-277011-A on regional c-Fos-like expression in rat forebrain". Brain Research 1149: 50–7.  
  3. ^ Reavill, C; Taylor, SG; Wood, MD; Ashmeade, T; Austin, NE; Avenell, KY; Boyfield, I; Branch, CL et al. (2000). "Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A". The Journal of Pharmacology and Experimental Therapeutics 294 (3): 1154–65.  
  4. ^ Le Foll, B; Schwartz, JC; Sokoloff, P (2003). "Disruption of nicotine conditioning by dopamine D(3) receptor ligands". Molecular psychiatry 8 (2): 225–30.  
  5. ^ Vorel, SR; Ashby Jr, CR; Paul, M; Liu, X; Hayes, R; Hagan, JJ; Middlemiss, DN; Stemp, G; Gardner, EL (2002). "Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats". Journal of Neuroscience 22 (21): 9595–603.  
  6. ^ Di Ciano, P; Underwood, RJ; Hagan, JJ; Everitt, BJ (2003). "Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A". Neuropsychopharmacology 28 (2): 329–38.  
  7. ^ Andreoli, M; Tessari, M; Pilla, M; Valerio, E; Hagan, JJ; Heidbreder, CA (2003). "Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior". Neuropsychopharmacology 28 (7): 1272–80.  
  8. ^ Ross, JT; Corrigall, WA; Heidbreder, CA; Lesage, MG (2007). "Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats". European Journal of Pharmacology 559 (2–3): 173–9.  
  9. ^ Xi, ZX; Gilbert, J; Campos, AC; Kline, N; Ashby Jr, CR; Hagan, JJ; Heidbreder, CA; Gardner, EL (2004). "Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats". Psychopharmacology 176 (1): 57–65.  
  10. ^ Ashby Jr, CR; Paul, M; Gardner, EL; Heidbreder, CA; Hagan, JJ (2003). "Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats". Synapse 48 (3): 154–6.  
  11. ^ Thanos, PK; Katana, JM; Ashby Jr, CR; Michaelides, M; Gardner, EL; Heidbreder, CA; Volkow, ND (2005). "The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats". Pharmacology, Biochemistry, and Behavior 81 (1): 190–7.  
  12. ^ Vengeliene, V; Leonardi-Essmann, F; Perreau-Lenz, S; Gebicke-Haerter, P; Drescher, K; Gross, G; Spanagel, R (2006). "The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse". The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20 (13): 2223–33.  
  13. ^ Heidbreder, CA; Andreoli, M; Marcon, C; Hutcheson, DM; Gardner, EL; Ashby Jr, CR (2007). "Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice".  
  14. ^ Joyce, JN; Millan, MJ (2005). "Dopamine D3 receptor antagonists as therapeutic agents". Drug Discovery Today 10 (13): 917–25.  
  15. ^ Jahnke, U (2008). "Experimental pharmacotherapeutics for schizophrenia and addiction". IDrugs : the investigational drugs journal 11 (1): 7–9.  
  16. ^ Malik, P; Andersen, MB; Peacock, L (2004). "The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia". Pharmacology, Biochemistry, and Behavior 78 (4): 805–10.  


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.